The Venture Codex Logo

The Venture Codex

Jude

15 Bishopsgate, London, Greater London, EC2N 3AR, United Kingdom

Overview

Jude builds products and services focused on bladder health, initially targeting women. Its core offering is a non-prescription bladder-strength supplement (pumpkin seed extract and soy germ extract) sold alongside absorbent pants, liners and pads. Jude operates a free support hotline staffed by trained specialists, a pelvic-floor exercise plan and a 4,000-member community; it also has a medical board and some in-house GPs. The company launched in the U.K. in January last year and has reached about 18,000 customers so far, projecting 4x U.K. usage in 12 months and roughly 100,000 customers next year as it expands to the U.S. Jude plans a digital consultation service and is applying for a U.K. medical licence for its supplement while pursuing patents and further studies to deepen product defensibility. The team intends to add more medical expertise (urologists/doctors) over time and to broaden its digital proposition and research partnerships. Jude builds consumer bladder-care products including fully biodegradable, 100% plant-based liners and pads alongside clinically tested bladder-strength supplements. Launched in January 2022 by founder Peony Li, the platform aims to destigmatise bladder issues and create a community around incontinence. The company has already shipped products to 2,600 customers. Jude recently raised £2 million in a pre-seed round to fund growth. Planned uses of capital include R&D to further develop affordable bladder-care solutions, running large-scale clinical supplements trials, expanding the marketing team, and producing educational content to break down taboos. The company positions its supplements as clinically tested formulations using botanicals shown to improve bladder care and associated wellbeing.

Total raised
$7M
Funding rounds
3
Latest round
Seed
Latest activity
Sep 2023

Industries

  • Consulting
  • Health Care
  • Health Diagnostics
Visit website

Recent funding

  1. Seed

    Sep 2023

    $4M

  2. Seed

    Mar 2022

    $3M

Team